Hepatocellular Carcinoma News and Research

RSS

Hepatocellular Carcinoma is a type of adenocarcinoma, the most common type of liver tumor.

Regorafenib drug improves survival rates in patients with hepatocellular carcinoma

Oral multikinase inhibitor regorafenib achieves significantly improved survival rates compared to placebo in patients with hepatocellular carcinoma, according to data from the phase III RESORCE trial, presented at the ESMO 18th World Congress of Gastrointestinal Cancer in Barcelona, Spain.

30 Jun 2016

HCC predictors identified for chronic HBV patients with newly diagnosed cirrhosis

In patients with chronic hepatitis B virus infection who have been newly diagnosed with cirrhosis, the risk of hepatocellular carcinoma development can be ascertained using several clinical and molecular factors, study findings indicate.

23 Jun 2016

Novel enzyme immunoassay helps diagnose HCV infection in one simple step

The current standard in diagnosing Hepatitis C virus (HCV) infection requires two sequential steps that make it suboptimal, costly, inconvenient, time consuming, and globally not widely available or affordable.

8 Jun 2016

Panel of microRNAs can predict patients at risk for developing HBV-driven liver cancer

Hepatocellular carcinoma, the most common type of liver cancer, is increasing in incidence in the United States, and infection with the Hepatitis B virus (HBV) causes about 50 percent of cases.

7 Jun 2016

Scientists debate role of AAV in causing hepatocellular carcinoma

Liver cancer can be triggered by mutations in cancer driver genes resulting from the insertion of adeno-associated virus (AAV) vectors used to deliver therapeutic genes, although this tumor-inducing role of AAV remains highly controversial.

27 May 2016

Researchers discover new potential treatment target for liver cancer

Researchers at the University of Eastern Finland and Eberhard Karls Universität Tübingen have discovered a new molecular mechanism that can be used to inhibit the growth of hepatocellular carcinoma, which is the most common liver cancer.

24 May 2016

High levels of p62 protein in liver linked to cancer recurrence

Researchers at University of California San Diego School of Medicine and Sanford Burnham Prebys Medical Discovery Institute have discovered that high levels of the protein p62 in human liver samples are strongly associated with cancer recurrence and reduced patient survival.

20 May 2016

FDA approves additional indication for Eisai's anticancer agent Lenvima in combo with Everolimus for advanced renal cell carcinoma

Eisai Co., Ltd. has announced that its U.S. subsidiary Eisai Inc. has received approval from the U.S. Food and Drug Administration (FDA) for an additional indication for Eisai's in-house developed novel anticancer agent Lenvima (lenvatinib mesylate) in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy.

16 May 2016

MUSC Hollings Cancer Center receives $8.9 million grant to explore signaling in sphingolipids

The Medical University of South Carolina's Hollings Cancer Center received an $8.9 million grant from the National Cancer Institute designed to foster collaboration across clinical and laboratory research for the study of signaling in sphingolipids, a class of lipids known to be involved in the growth of solid tumor cancers.

10 May 2016

High-level quantum chemical computations help unravel underlying mechanism of hepatocellular toxicity

Balasubramanian and Basak have recently reported quantum chemical computations that enhance our understanding of mechanisms for the causes of liver toxicity. Hepatocellular carcinoma is one of the most common forms of cancer, and the primary cause has been attributed to liver fibrosis by chemical toxins, which is followed by liver cirrhosis.

9 May 2016

Antiviral therapies equal survival rate of HCV-related cirrhosis patients with general population

The survival rate of patients with hepatitis C virus-related cirrhosis who respond well to antiviral therapies equals that of the general population, say investigators in the Journal of Hepatology.

5 May 2016

Bayer-new phase 3 liver cancer data

Bayer has announced that a Phase III trial evaluating its oncology compound Stivarga® (regorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met its primary endpoint of a statistically significant improvement in overall survival. The study, called RESORCE, evaluated the efficacy and safety of regorafenib in patients with HCC whose disease has progressed after treatment with sorafenib. The safety and tolerability were generally consistent with the known profile of regorafenib. Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress.

4 May 2016

HBcrAg may predict HCC development

Research suggests a role for hepatitis B core-related antigen in the prediction of hepatocellular carcinoma development in nucleos(t)ide analogue treatment-naïve patients with chronic hepatitis B virus infection.

27 Apr 2016

WFA+-M2BP levels linked to liver fibrosis, HCC progression in chronic HBV

Japanese researchers have found that serum levels of glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein are a useful marker of not only the degree of liver fibrosis, but also progression to hepatocellular carcinoma in patients with chronic hepatitis B virus infection.

27 Apr 2016

HCV patients with hepatocellular carcinoma history could re-develop illness during or after taking DAAs

Data from a new study show that patients with Hepatitis C virus (HCV) taking direct-acting antiviral treatments (DAAs), who have previously fought off hepatocellular carcinoma (HCC), the most common form of liver cancer,1 had a 'high rate' of re-developing their illness.

13 Apr 2016

DAA medication could lead to revolution in hepatitis C treatment

The cost of treating hepatitis C virus (HCV) could be cut up to 50 percent if mathematical models are used to predict when patients can safely stop taking direct-acting antiviral (DAA) medication, according to a new study by researchers at Loyola University Health System and Loyola University Chicago

23 Mar 2016

Dietary broccoli may protect against liver cancer

Consumption of broccoli has increased in the United States over the last few decades as scientists have reported that eating the vegetable three to five times per week can lower the risk of many types of cancer including breast, prostate, and colon cancers.

4 Mar 2016

Structural movie reveals step-by-step creation of chemical that plays important role in some cancers

An international team of scientists led by the University of Liverpool has produced a 'structural movie' revealing the step-by-step creation of an important naturally occurring chemical in the body that plays a role in some cancers.

10 Feb 2016

Experimental nanoparticle therapy shows promise for fighting primary liver cancer

An experimental nanoparticle therapy that combines low-density lipoproteins (LDL) and fish oil preferentially kills primary liver cancer cells without harming healthy cells, UT Southwestern Medical Center researchers report.

9 Feb 2016

Cistus extracts attack HIV and Ebola viruses

Scientists at the Helmholtz Zentrum München discover that extracts of the medicinal plant Cistus incanus (Ci) prevent human immunodeficiency viruses from infecting cells. Active antiviral ingredients in the extracts inhibit docking of viral proteins to cells. Antiviral activity of Cistus extracts also targets Ebola- and Marburg viruses.

3 Feb 2016